GENEVA, August 11, 2026, 10:08 CEST
- Alcon stock climbed 5.7%, while the STOXX 600 advanced 0.1%.
- The eye-care company increased its core profit outlook for 2026 for the second time.
- The company now estimates its tariff expenses at $40 million-$90 million, down from $100 million-$150 million.
- The midpoint drop reflects an anticipated $60 million U.S. refund.
Shares in Alcon Inc. (SWX:ALC; NYSE:ALC) rose 5.7% on Tuesday after the company raised its 2026 core profit guidance for a second time and significantly lowered its projected tariff costs.
The stock surpassed a mostly unchanged European market by 5.6 percentage points, ranking Alcon among the top-performing large-cap stocks in the region during early trading.
| Early Tuesday market action | Change |
|---|---|
| Alcon | +5.7% |
| STOXX Europe 600 | +0.1% |
| Alcon’s outperformance versus index | +5.6 percentage points |
Market comparison reflects prices as of 07:17 GMT, when Swiss markets were trading. U.S. cash markets had yet to open.
The investor side is unusually straightforward. Alcon reduced the midpoint of its tariff projection by $60 million, lowering it from $125 million to $65 million. This matches the expected reimbursement from the U.S. government.
The company does not view it as an outright windfall. Management plans to reinvest around two-thirds of the refund, with the remaining portion expected to be approximately $20 million before tax, according to the company’s estimates.
| 2026 outlook | May view | August view | Change |
|---|---|---|---|
| Net sales growth, constant currency | 5%-7% | 5%-7% | Unchanged |
| Core operating-margin expansion, constant currency | 70-170 basis points | 90-190 basis points | Increased by 20 basis points |
| Core diluted EPS growth, constant currency | 10%-13% | 12%-15% | Up 2 percentage points |
| Estimated tariff cost | $100 million-$150 million | $40 million-$90 million | Lower by $60 million at midpoint |
The August outlook maintains constant-currency sales growth between 5% and 7%. It increases both the lower and upper bounds of the margin range by 20 basis points, and raises both ends of the EPS range by two percentage points.
Sales remained the main driver. Revenue for the second quarter increased 8% to $2.782 billion. Adjusted for currency, growth reached 7%, slightly surpassing market forecasts.
Core operating income rose 17% to $574 million. Core diluted earnings climbed 11% on a reported basis to $0.84.
| Second-quarter measure | 2026 | 2025 | Reported change |
|---|---|---|---|
| Net sales | $2.782 billion | $2.577 billion | +8% |
| Core operating income | $574 million | $491 million | +17% |
| Core operating-margin change | Year-over-year | +1.5 percentage points | |
| Core diluted EPS | $0.84 | Not disclosed in summary | +11% |
Alcon reports its core metrics as non-IFRS. Under IFRS, quarterly operating income declined to $11 million compared with $247 million, following a pre-tax, non-cash charge of $402 million.
Alcon recorded the charge after opting to discontinue the PowerVision intraocular-lens programs. The company reported that recent clinical results showed unpredictable post-surgical outcomes in certain patients.
New offerings helped balance out the decline. Sales of equipment and ocular-health items saw the most rapid growth, as implantables continued to lag.
| Second-quarter product line | Sales | Constant-currency growth |
|---|---|---|
| Equipment and other | $279 million | up 25% |
| Ocular health | $486 million | up 12% |
| Consumables | $825 million | up 5% |
| Contact lenses | $726 million | up 5% |
| Implantables | $466 million | up 1% |
Expansion in equipment was driven by new systems, such as Unity. Ocular health was supported by Tryptyr and Systane products, though implantables were impacted by competitive challenges.
Chief Executive David J. Endicott said, “Our team delivered strong second-quarter results and executed well across the business.” He pointed to Unity, PanOptix Pro and Tryptyr as contributors to growth. Alcon earnings release
The U.S. accounted for 45% of sales in the first half. Alcon’s main production facilities are also primarily located in the country, reducing its reliance on imported finished products.
Risks persist. The refund is projected for the third quarter but has not yet arrived. Alcon’s forecast is also based on present U.S. tariff rates of roughly 10%-12.5% remaining unchanged until December.
The next hurdle is execution. Sales guidance remained unchanged, and two-thirds of the refund is set aside for reinvestment. Investors will look to see if new products can sustain the 90-190 basis point increase in margins.
Related articles: Stock Market
